Dr. Braciak has been testing combinatory therapies designed to alter the tumor microenvironment as well as elicit T and/or NK cell responses to affect the treatment of prostate cancer. The tumor microenvironment can negatively affect tumor immune response and needs to be one of the targets in multifaceted therapeutic tumor regimens. In this research, one strategy is to use gene therapy with a recombinant adenovirus expressing interleukin-12 (Ad5IL-12) for intratumor injection to alter the tumor microenvironment to make it more favorable to elicited tumor immune response.

<< Breast Cancer | Leukemia and Lymphomas >>